- Mirimus Inc has collaborated with Biogen Inc BIIB to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
- Terms of the collaboration are not disclosed.
- Under the agreement, Mirimus will engineer RNAi-based therapeutics that Biogen will assess to determine feasibility in potential neurological disease settings.
- If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).
- Price Action: BIIB shares are down 0.75% at $320.06 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
